Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2017
Reporting Period: This filing announces financial results for the three and six months ended June 30, 2017. The specific financial data is contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed figures. The filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus prior comparable periods. It only confirms the issuance of results for the periods ended June 30, 2017.
Guidance, Outlook, and Risks
Management Commentary: The report was signed by Gregory A. Demopulos, M.D., President, CEO, and Chairman of the Board.
Legal Disclaimer: The information in this 8-K and the accompanying exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings by the company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2017) for actual revenue, net loss, and cash position figures.
- Verify the specific performance of the company's drug candidates and clinical trial progress mentioned in the press release.
- Confirm the company's cash runway and any recent financing activities detailed in the full press release.
- Note that this 8-K filing explicitly excludes the financial data from being incorporated by reference into future filings.